Targeting Progressive Neuroaxonal Injury: Lessons from Multiple Sclerosis

ISSN： 1172-7047

Source： CNS Drugs, Vol.25, Iss.9, 2011-09, pp. : 783-799

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of Secondary-Progressive Multiple Sclerosis

By Gavin Giovannoni

CNS Drugs, Vol. 18, Iss. 10, 2004-01 ,pp. : 653-669

Adis International

Access to resources Recommend Favorite

Targeting Apoptosis to Treat Multiple Sclerosis

Current Drug Discovery Technologies, Vol. 5, Iss. 1, 2008-01 ,pp. : 75-77

Bentham Science Publishers

Access to resources Recommend Favorite

Rituximab for Secondary Progressive Multiple Sclerosis: A Case Series

By Rommer Paulus S. Patejdl Robert Winkelmann Alexander Benecke Reiner Zettl Uwe K.

CNS Drugs, Vol. 25, Iss. 7, 2011-07 ,pp. : 607-613

Adis International

Access to resources Recommend Favorite

Paclitaxel therapy is promising in secondary progressive multiple sclerosis

Inpharma, Vol. 1, Iss. 1227, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Patients with secondary progressive multiple sclerosis (MS) may not benefit from treatment with IV immunoglobulin G (IVIG)

Inpharma, Vol. 1, Iss. 1457, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite